65.42
-7.48
(-10.26%)
As of 8:00:42 AM GMT+2. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 13 | 13 | 19 | 19 |
| Avg. Estimate | 265.02M | 284.11M | 1.19B | 1.45B |
| Low Estimate | 253.8M | 276.8M | 1.16B | 1.38B |
| High Estimate | 271.4M | 288.9M | 1.23B | 1.51B |
| Year Ago Sales | 223.85M | 235.25M | 975.18M | 1.19B |
| Sales Growth (year/est) | 18.39% | 20.77% | 21.78% | 22.18% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 7FP.F | -- | -- | -- | -- |
| S&P 500 | 6.55% | 6.50% | 9.70% | 14.29% |
Upgrades & Downgrades
| Maintains | Wells Fargo: Overweight to Overweight | 4/2/2025 |
| Maintains | Truist Securities: Buy to Buy | 3/31/2025 |
| Maintains | Piper Sandler: Overweight to Overweight | 3/25/2025 |
| Downgrade | Oppenheimer: Outperform to Perform | 3/11/2025 |
| Maintains | Stifel: Buy to Buy | 3/10/2025 |
| Maintains | JP Morgan: Neutral to Neutral | 3/10/2025 |